CELL INTELLIGENCE · 肿瘤细胞治疗研究

NK 细胞上的 TIM3 调控 HER2 阳性胃癌中的抗体依赖性细胞介导的细胞毒性

TIM3 on natural killer cells regulates antibody-dependent cellular cytotoxicity in HER2-positive gastric cancer.

人表皮生长因子受体 2 阳性晚期胃癌或食管胃腺癌：回顾过去以获得新见解

Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.

曲妥珠单抗，一种抗 HER2 的单克隆抗体，通过多种机制调节对胆管癌的细胞毒性作用

Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms.

骨肉瘤 HER2 靶向治疗的未来：德曲妥珠单抗阴性结果的启示

The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.

干扰素基因刺激因子（STING）表达下调和 CD8(+) T 细胞浸润取决于 HER2 阳性胃癌中 HER2 的异质性

Down-regulation of stimulator of interferon genes (STING) expression and CD8(+) T-cell infiltration depending on HER2 heterogeneity in HER2-positive g

我们的结果表明，在 HER2 阳性 GC 中，HER2 信号可能通过抑制肿瘤细胞中的 STING 信号来抑制 GC TME 中的免疫细胞活化。

经治胃癌患者的药物治疗：当前选择与未来进展

Pharmacotherapy for previously treated gastric cancer patients: current options and future developments.

生物标志物驱动的治疗有望在未来成为主流方法。

癌症中抗体-药物偶联物的耐药机制

Mechanisms of resistance to antibody-drug conjugates in cancers.

晚期胃癌中的 Claudin18.2

Claudin18.2 in Advanced Gastric Cancer.